Investing in RetinaLogik | Ep 32 episode artwork

EPISODE · Dec 9, 2024 · 20 MIN

Investing in RetinaLogik | Ep 32

from Allied Angels: Venture Capital Insights · host Allied Venture Partners

In this episode of Allied Angels, we shine a spotlight on our exciting new investment in RetinaLogik, a revolutionary healthtech company poised to transform the landscape of vision care. With its innovative AI/VR-powered eye exam platform, RetinaLogik is set to redefine how eye exams are conducted, making them more accessible and efficient.Join us as we explore:• Transformative Technology: Discover how RetinaLogik's proprietary machine learning and AI algorithms enable a suite of eye exams that can be easily administered through off-the-shelf VR headsets. These exams have been clinically validated to match the accuracy of traditional gold-standard tests, addressing critical inefficiencies in the current eye care model.• Streamlined Eye Care Delivery: Learn about RetinaLogik's mission to replace up to 85% of existing eye exams by consolidating multiple tests into a single, hardware-agnostic VR headset. This innovative approach simplifies clinic operations and expands access to vision care for individuals unable to visit clinics.• Proven Leadership: Dr. Abed Sarhan, Co-Founder and CEO of RetinaLogik, whose deep domain expertise in machine learning and ophthalmology drives the company’s mission. His unique combination of academic and practical experience positions RetinaLogik for success in creating transformative solutions.• Market Opportunity: Explore the vast potential of the North American vision care market, projected to reach $33.5 billion by 2028. We discuss the intersection of rising VR adoption, advancements in AI, and the growing demand for operationally efficient technologies in the eye care sector.• Impressive Early Traction: Hear about RetinaLogik's strong early performance, including thousands of administered eye exams, hundreds of enterprise customers, and consistent month-over-month growth. We'll highlight how 95% of patients prefer RetinaLogik's experience over traditional exams.• Competitive Edge: Understand how RetinaLogik's proprietary intellectual property and distribution model provide a significant competitive advantage, allowing for rapid scale and market adoption.• Vision for the Future: As we look ahead, we discuss how RetinaLogik is strategically positioned at the forefront of a major technological transformation in the global eye care industry, projected to reach $173 billion by 2031.This episode is a must-listen for those interested in the intersection of technology and healthcare, as we explore how RetinaLogik is revolutionizing vision care through innovation and strategic investment.Key Takeaways:• Insights into RetinaLogik's AI/VR technology and its impact on vision care.• The significance of leadership and market opportunity in healthtech investments.• Early traction metrics that highlight RetinaLogik's potential for success.------------⁠Allied VC⁠ is Western Canada's largest angel syndicate, investing in early-stage technology startups across Canada and the USA.Pitch us, Invest, Scout, and more: ⁠⁠https://linktr.ee/alliedvc⁠⁠Allied Angels is powered by NotebookLM - Google's new AI note-taking & research assistant.

Episode metadata supplied by the publisher feed · Published Dec 9, 2024

Embed this episode

Ready to play

Investing in RetinaLogik | Ep 32

0:00 20:37

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Allied Angels: Venture Capital Insights?

This episode is 20 minutes long.

When was this Allied Angels: Venture Capital Insights episode published?

This episode was published on December 9, 2024.

Can I download this Allied Angels: Venture Capital Insights episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!